Several treatments may be effective In chronic inflammatory demyelinating polyneuropathy (CIDP). 6 To maintain the best possible functional health status patients may need protracted treatment. 7 Recently, remissions after treatment with pulsed high dose dexamethasone have been reported in patients with chronic idiopathic thrombocytopenic purpura (ITP).8 There are similarities in treatment response between ITP and CIDP. The first treatment of a patient with CIDP with intravenous immunoglobulins (IVIg) was based on the reports of a beneficial effect of similar treatment in ITP. 9 The effects of IVIg and plasma exchange, however, are often short lived in patients with ITP and CIDP and many patients who are treated with corticosteroids have a relapse when the dosage is reduced.
Six cycles of four sequential days with 40 mg dexamethasone per day every 28 days was studied in 10 patients with a relapse of ITP after standard treatment. All 10 patients had increased platelet counts, which remained stable for at least six months after the last dexamethasone cycle.8 Serious side effects did not occur and this treatment was well tolerated by the patients.
We treated 10 patients with CIDP with pulsed high dose dexamethasone. The first question was whether this therapy induces remission in patients with CIDP. The second question was whether these patients had clinically significant improvement. deterioration occurred, the neurologist in charge of the patient carried out an evaluation. Side effects were assessed after each cycle.
Material and methods
We analysed the number of patients who reached remission of at least six months, the changes in functional health scores of each patient, and the side effects of treatment.
Results
The table shows the characteristics of the 10 patients. Nine patients had a mixed sensorimotor neuropathy and one (7) had a symmetric, pure motor neuropathy. Six patients had a relapsing-remitting course before dexamethasone treatment was started. Five of these (1, 2, 5, 6, 7) had previously shown a beneficial response to IVIg and one (3) had not responded to IVIg but improved after prednisone and azathioprine. There were four patients (4, 8, 9, 10) newly diagnosed with CIDP. Two patients (4, 9) had a chronic progressive course and two (8, 10) had a chronic progressive course with fluctuations in neurological signs and symptoms. One of these two patients had an IgA nephropathy which had probably not caused his neuropathy.
Three patients (3, 7, 9) did not complete dexamethasone treatment. In one patient (3) treatment was stopped because of severe nausea, vomiting, and weight gain during treatment. Dexamethasone was started because she had a relapse while taking 20 mg prednisone daily. After two cycles, dexamethasone was stopped and prednisone was continued. Her neurological signs and symptoms slowly improved. In two patients treatment was stopped because of deterioration of neurological signs and symptoms. One (7) had a pure motor form of CIDP, with a beneficial response to IVIg. He deteriorated dramatically after dexamethasone, and later also after three days of 1 g intravenous methylprednisolone and after five days of 500 mg intravenous methylprednisolone, but each time he again improved after IVIg. He reached the maximum RMI score after IVIg, but was still dependent on repeated IVIg infusions. The second patient (9) 12 By contrast with the patients with ITP, our patients were not refractory to other treatments. Four of seven patients who responded to dexamethasone treatment had responded to IVIg during previous relapses and three of the seven patients had not been treated before.
Although not all of these patients with CIDP reached remission after six months, the results of this study are promising when compared with other studies that analysed remission in CIDP.' [13] [14] [15] [16] [17] [18] [19] Up to 70% of the patients with CIDP relapse when the dose of steroids is reduced and treatment schedules lasting two years have been recommended. 16 Of 41 patients with CIDP who responded to IVIg, 73% needed repeated immunoglobulin infusions for at least six months, and 50% still needed treatment after two years. '4 This pilot study suggests that pulsed high dose dexamethasone treatment may induce clinically significant improvement and remissions in a substantial proportion of patients with CIDP. The side effects are acceptable when remissions are sustained. This treatment regimen of steroids needs to be tested against standard treatments for CIDP. 
